After two decades of policy focus, China has big advantages. But the U.S. still has ways to get in on the Africa game
Coca-Cola’s North America president, Sandy Douglas, oversees a relaunch of America’s No. 1 soft drink
New rules are intended to encourage federal contractors to settle, rather than risk violations that can cost them government work
How will strapping on Google Glass or a smart watch when you're at work affect privacy and productivity?
Lisbon is not Paris. But Portuguese taxes have their allure
The drab choking poster is getting a makeover by artists, whether it needs it or not
Women are increasingly downing hard alcohol at work events. So what should you order? A female bartender creates the perfect networking cocktail
According to a business school professor with years of research in negotiation bias toward women, flirting can't be ruled out as a strategy
The historic house called Stetson Mansion gets top marks on TripAdvisor
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."